Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Guardant Health (GH) Wins FDA Approval For First Liquid Biopsy In Advanced Breast Cancer

5 September 2026 · By · Wire by Fusion42

Published

5 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at simplywall.st →

◆ Verified

Fusion42 · 5 September 2026 · Fusion42 review

Guardant Health received FDA approval for Guardant360 CDx, the first liquid biopsy companion diagnostic to monitor circulating tumor DNA for early progression detection in advanced breast cancer, enabling adaptive treatment decisions before radiographic progression.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

FDA approval for liquid biopsy shifts breast cancer testing towards noninvasive, regular monitoring. You in biotech or diagnostics must engage oncologists and payers now to capture early adoption in this expanding test market.

◆ Coverage

2 sources · 5 Sep 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalliquid-biopsybreast-cancerprecision-oncologycancer-diagnostics